Document resource
Background Recent evidence supports the use of disease-modifying therapies (DMTs) in early Alzheimer’s disease (AD). Lecanemab and donanemab have received FDA approval and could be introduced into UK clinical practice pending NICE approval. This would require an assessment of eligibility and an estimation of the capacity needed for the safe delivery of these therapies at clinical sites. This study aimed to estimate the proportion of patients seen in our neurology-led clinics in Nottingham who might be eligible for DMTs.Methods The CogNID study (IRAS 250525) focuses on patients with Mild Cognitive Impairment (MCI) who are referred to neurology-led clinics at Nottingham University Hospitals NHS Trust for further investigation. We analysed clinical, cognitive, neuroimaging and CSF biomarker data collected from MCI patients to estimate the proportion potentially eligible for DMTs.Results Among the 429 MCI patients who participated in CogNID study, 111 (25.9%) were diagnosed with possible clinical diagnosis of AD. Of these, 70 (63.1%) met cognitive criteria for DMT eligibility, with one excluded based on MRI criteria. Thus, 69 patients (16.1%) were potentially eligible for DMTs (mean age:63 ± 8 years; 64%:male;ethnicity: 59% White British).Conclusions Approximately 16% of patients seen in our neurology-led tertiary referral clinics may be eligible for DMTs.priya.sharma15@nhs.net